3-{2-[4-(2-ethyl-5-methoxy-1H-1,3-benzodiazol-1-yl)phenyl]ethyl}-1-[(4-methylbenzene)sulfonyl]urea | 415903-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-{2-[4-(2-ethyl-5-methoxy-1H-1,3-benzodiazol-1-yl)phenyl]ethyl}-1-[(4-methylbenzene)sulfonyl]urea
• 英文别名: 1-[2-[4-(2-Ethyl-5-methoxybenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea
• CAS: 415903-76-3
• 化学式: C₂₆H₂₈N₄O₄S
• 分子量: 492.599
• InChiKey: BVWWSZFRFHWGAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Use of EP4 receptor antagonists in the treatment of cartilage disease
  申请人：AskAt Inc.

  公开号：US10391086B2

  公开（公告）日：2019-08-27

  The invention is a method of treating osteoarthritis or normalizing a condition of osteoarthritis comprising administering to an animal or a human in need thereof a therapeutically effective amount of 3-[2-(4-2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof.

  本发明是一种治疗骨关节炎或使骨关节炎病情正常化的方法，包括向需要的动物或人类施用治疗有效量的 3-[2-(4-2-乙基-4,6-二甲基-1H-咪唑并[4,5-c]吡啶-1-基}苯基)乙基]-1-[(4-甲基苯)磺酰基]脲或其药学上可接受的盐。
• USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES
  申请人：RaQualia Pharma Inc

  公开号：EP2538978A1

  公开（公告）日：2013-01-02
• USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE
  申请人：AskAt Inc.

  公开号：EP2976105A1

  公开（公告）日：2016-01-27
• US9457084B2
  申请人：——

  公开号：US9457084B2

  公开（公告）日：2016-10-04
• [EN] USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES<br/>[FR] UTILISATION D'ANTAGONISTES DE RÉCEPTEUR EP4 DANS LE TRAITEMENT DE MALADIES MÉDIÉES PAR IL-23
  申请人：RAQUALIA PHARMA INC

  公开号：WO2011102149A1

  公开（公告）日：2011-08-25

  This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of immune disease or allergy in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.